The Framingham Offspring Study
R
esistance to insulin-mediated glucose uptake is an emerging risk factor for coronary heart disease (CHD), although the precise mechanism by which increased risk is conferred is uncertain. Insulin may have direct toxic effects on vascular endothelium, or may act through atherogenic effects of the constellation of risk factors associated with the insulin resistance syndrome (1, 2) . Associations between insulin levels and incident CHD have been reported in some but not all studies, suggesting that other factors may be involved in the link between hyperinsulinemia and atherosclerosis (3) (4) (5) . One such factor may be allelic variation at the apolipoprotein (apo) E gene locus.
Apo(e) is a plasma protein modulating metabolism of atherogenic plasma lipoproteins, particularly apoB-containing lipoproteins. The apo(e) gene locus is polymorphic; 3 alleles, e2, e3, and e4, encode 6 isoforms of the plasma protein. Compared with the e3 allele, total and LDL cholesterol levels are lower in people with the e2 allele and higher in those with the e4 allele, and both the e2 and e4 alleles are associated with elevated triglyceride levels, at least among men (6) . The apo(e) polymorphism is itself an emerging risk factor for CHD, with the e4 allele in particular conferring increased risk for CHD independent of associated elevated total and LDL cholesterol levels (6) (7) (8) (9) (10) (11) (12) (13) .
Associations between insulin levels or insulin resistance and apo(e) phenotypes are not well characterized. Limited data suggest that apo(e) phenotypes may modify the effect of insulin on CHD or some CHD risk factors, including BMI, total and LDL cholesterol levels, and triglyceride levels (14) (15) (16) (17) (18) . We assessed the relationship between insulin resistance, measured by homeostasis model assessment (HOMA-IR) (19) , and apo(e) phenotype and allele frequencies in the population-based Framingham Offspring Study. In addition, we assessed whether apo(e) phenotypes modify well-recognized associations between insulin resistance and metabolic features of the insulin resistance syndrome.
Apo(e) isoforms and insulin resistance

RESEARCH DESIGN AND METHODS
Study population
Participants in the Framingham Offspring Study, a long-term community-based prospective observational study of risk factors for cardiovascular diseases, are the children and spouses of the children of the original Framingham Heart Study cohort. Of 1,404 original Heart Study cohort couples, 86% were represented by at least 1 child in the Offspring Study, and of the 3,717 children of these couples, 71% participated in the Offspring Study (20) . From January 1991 through June 1995 (examination cycle 5), 3,799 participants fasted overnight, had a standardized medical history, as well as physical and laboratory examination, and those without diagnosed diabetes had an oral glucose tolerance test (OGTT). The OGTT results were interpreted with the 1997 American Diabetes Association criteria (21) . Diagnosed diabetes was defined as a fasting plasma glucose level Ն7.0 mmol/l at any 2 previous examinations or the use of hypoglycemic drug therapy. Previously undiagnosed diabetes was defined as a fasting plasma glucose level Ն 7.0 mmol/l or a 2-h postchallenge glucose level Ն11.1 mmol/l. Impaired glucose tolerance (IGT) was defined as a fasting plasma glucose level Ն6.1 and Ͻ7.0 mmol/l and a 2-h postchallenge glucose level Ն7.0 and Ͻ11.1 mmol/l. Of the 3,799 participants, we excluded 204 with previously diagnosed or OGTT-diagnosed diabetes, 171 with missing information on insulin resistance or glucose tolerance status, and 1,508 who did not have their apo(e) phenotype measured. Data from the remaining 1,916 participants are included here. Diabetic subjects were excluded because HOMA-IR may not reliably estimate insulin resistance in diabetes and because diabetes is a consequence, not a feature, of the insulin resistance syndrome. Subjects without apo(e) phenotype data were younger (54 vs. 55 years, P = 0.0003) and more likely to be women (55% women vs. 45% men, P = 0.003) than those with phenotype data. There was no difference in the distributions of glucose tolerance status or HOMA-IR when comparing subjects with and without apo(e) phenotype information.
Laboratory methods
Fasting plasma glucose was measured in fresh specimens with a hexokinase reagent kit (A-gent glucose test; Abbott, South Pasadena, CA). Glucose assays were run in duplicate; the intra-assay coefficient of variation (CV) was Ͻ3%. The fasting total plasma cholesterol and plasma triglyceride levels were measured enzymatically (22) , and the HDL cholesterol (HDL-C) fraction was measured after precipitation of LDL and VLDL with dextran sulfate-magnesium (23) . LDL cholesterol (LDL-C) was estimated indirectly using the Friedewald formula for people with plasma triglyceride levels Ͻ4.52 mmol/l (24) . The Framingham laboratory participates in the lipoprotein cholesterol laboratory standardization program administered by the Centers for Disease Control and Prevention in Atlanta, Georgia. Fasting insulin was measured in EDTA plasma as total immunoreactive insulin (Coat-A-Count Insulin; Diagnostic Products, Los Angeles, CA) and calibrated to serum levels for reporting purposes. Cross-reactivity of this assay with proinsulin at midcurve is ϳ40%, the intra-and interassay CV ranged from 5.0 to 10.0% for concentrations reported here, and the lower limit of sensitivity was 8 pmol/l. Apo(e) isoforms were measured in a random subset of participants at the third examination cycle (1983) (1984) (1985) (1986) (1987) ) from plasma VLDL, after ultracentrifugation at a plasma density of 1.006 kg/l. The isolated VLDL particles were lypohilized, delipidated, and subjected to isoelectric focusing within a pH range of 4.0-6.5 (25) .
Assessment of insulin resistance and apo(e) phenotype
We used the homeostatic model to assess insulin resistance, where HOMA-IR = fasting insulin ϫ glucose/22.5 (19) . HOMA-IR provides a reliable estimate of insulin resistance across the range of glucose tolerance using either the frequently sampled intravenous glucose tolerance test (FSIGTT) with minimal model analysis or the glucose clamp technique as the gold standard measure of insulin sensitivity (26, 27) . Subjects were categorized into quintiles of HOMA-IR, with levels in the first quintile ranging from 2.30 to 4.90; the second quintile, 4.91 to 5.80; the third quintile, 5.81 to 6.80; the fourth quintile, 6.81 to 8.50; and the fifth quintile, 8.51 to 31.1. Apo(e) phenotypes were assigned according to apo(e) isoform 3/3, 2/2, 2/3, 3/4, 4/4, or 2/4. Apo(e) allele prevalence was calculated by summing isoform frequencies using balanced-gene estimates. For example, the prevalence of the e2 allele = prevalence of [apo(e) 2/2 ϩ 1/2 ϫ (apo(e) 2/3 ϩ apo(e) 2/4)] (28).
Insulin resistance syndrome features and lipid risk factor definitions Subjects were classified with each of 6 basic features of the insulin resistance syndrome (2) and with elevated LDL or total cholesterol levels. Hypertension was defined as a blood pressure Ͼ140/90 mmHg on both of the measurements or report of antihypertensive medication use (29) . Height, weight, waist, and hip circumference were measured. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m 2 ); obesity was defined as BMI Ն27.8 kg/m 2 in men or Ն27.3 kg/m 2 in women (the National Health and Nutrition Examination Survey II 85th percentiles), corresponding to ϳ120% ideal body weight (30). Central obesity was defined as a waist-to-hip ratio (WHR) Ͼ1.0 in men or Ͼ0.9 in women, corresponding to Ͼ85th percentile in this population. High triglyceride levels were defined as a fasting plasma triglyceride level Ն2.51 mmol/l, low HDL-C levels as HDL-C Յ0.91 mmol/l in men or Յ1.16 mmol/l in women, high LDL-C levels as LDL-C Ն4.14 mmol/l, and high total cholesterol levels as total cholesterol Ն6.21 mmol/l (31).
Statistical analysis
We assessed the statistical significance of differences in proportions of apo(e) isoform and allele frequencies across quintiles of increasing HOMA-IR using 2 tests (32) . Proportions of subjects with insulin resistance syndrome features or elevated lipid risk factors were adjusted for age and sex using logistic regression (33) . Logistic regression models were used to assess trends in age-, sex-, and apo(e) isoform-adjusted proportions of characteristics across HOMA-IR quintiles, and to assess pair-wise differences in age-, sex-, and HOMA- 
Data are n or proportions. Data are percentages with each insulin resistance syndrome characteristic. NS, P Ն 0.05. *Also adjusted for apo(e) isoform. †Also adjusted for HOMA-IR. P values are for pair-wise differences in percentages with insulin resistance syndrome characteristics between apo(e) isoform type.
insulin resistance syndrome features or lipid risk factors were characteristic of similar U.S. Caucasian populations (35) . The distributions of apo(e) isoform and allele frequencies were not associated with insulin resistance. Table 2 demonstrates that proportions of all apo(e) isoform or allele types were constant across increasing quintiles of HOMA-IR. There were more men than women in the upper quintiles of HOMA-IR (P Ͻ 0.0001 comparing trends across quintiles), but there were no significant differences between men and women in the distribution of apo(e) isoforms across quintiles of HOMA-IR. Results were essentially identical when subjects with IGT were excluded from frequency distribution analyses, or when fasting or 2-h postchallenge insulin levels were used instead of HOMA-IR as an index of insulin resistance.
As expected, the prevalence of nonlipid insulin resistance syndrome features increased across quintiles of HOMA-IR, but there were no significant differences in proportions with IGT, hypertension, obesity, or increased WHR between apo(e) isoform types (Table 3) (36) . Interaction terms between apo(e) and HOMA-IR, in models predicting presence of insulin resistance syndrome features, were not statistically significant, indicating that apo(e) isoform type did not modify the effect of HOMA-IR on their prevalence.
The prevalence of low HDL-C or high triglyceride levels also increased across quintiles of HOMA-IR (Table 4 ). In addition, there were significant differences in the proportions of these insulin resistance syndrome-related lipid features between apo(e) isoform types. Low HDL levels were more frequent comparing subjects with apo(e) isoforms (3/4, 4/4) to those with isoform 3/3 (overall age-, sex-, and HOMA-IR-adjusted proportions 28.8 vs. 20.3%, P = 0.0006) or isoforms (2/2, 2/3) (28.8 vs. 21.5%, P = 0.03). Apo(e) isoform type did not modify the effect of increasing HOMA-IR on the prevalence of a low HDL-C. Although overall differences in triglyceride levels appeared similar across apo(e) phenotypes, there was a significant interaction by apo(e) isoform type on the association between increasing insulin resistance and high triglyceride levels. In the lowest quintile of HOMA-IR, the prevalence of high triglycerides among those with isoforms (2/2, 2/3) was significantly higher than among those with isoform 3/3 (9.1 vs. 3.7%, P = 0.006 for the overall adjusted difference in proportions) or isoforms (3/4, 4/4) (9.1 vs. 4.6%, P = 0.01), but the prevalence comparing isoform 3/3 with isoforms (3/4, 4/4) was similar (3.7 vs. 4.6%, P = 0.7). This pattern was reversed in the highest quintile of HOMA-IR, in which the prevalence of high triglycerides among those with isoforms (2/2, 2/3) was significantly lower than among those with isoform 3/3 (22.5 vs. 33.8%) or isoforms (3/4, 4/4) (22.5 vs. 39.8%). The increase in prevalence of high triglyceride levels across quintiles of HOMA-IR was similar comparing subjects with isoform 3/3 to those with isoforms (3/4, 4/4) (P = 0.3 for interaction). Associations between HOMA-IR, apo(e) isoform type, and triglyceride levels were similar comparing men and women (P Ն 0.05 for first-and second-order interaction terms for these effects).
Elevated total or LDL-C levels are not classically described features of the insulin resistance syndrome, but, in this study sample, the prevalence of these lipid risk factors increased significantly, though modestly, with increasing HOMA-IR (Table 4 ; P = 0.0009 for trend in total cholesterol across quintiles, P = 0.03 for LDL-C). Apo(e) isoform type did not modify the effect of increasing HOMA-IR on the prevalence of these lipid risk factors. Pair-wise comparisons in proportions with high, total, or LDL-C levels among subjects with apo(e) isoforms (2/2, 2/3) (overall adjusted prevalence of high total cholesterol, 9.6% and high LDL-C, 9.8%), isoform 3/3 (total cholesterol, 15.8% and LDL-C, 14.8%), or iso-
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Apo(e) isoforms and insulin resistance Data are percentages with each lipid risk factor. NS, P Ն 0.05; *also adjusted for apo(e) isoform; †also adjusted for HOMA-IR. P values are for pair-wise differences in percentages with insulin resistance syndrome characteristics between apo(e) isoform type.
forms (3/4, 4/4) (total cholesterol, 20.2% and LDL-C, 19.5%) were all significant.
CONCLUSIONS -In the large unselected population-based Framingham Offspring Study, apo(e) allele frequencies were similar to those in other Caucasian populations (35) . We found that these allele frequencies, and the distribution of apo(e) isoforms they encode, remained constant across increasing quintiles of HOMA-IR. Further, apo(e) isoform type did not modify most associations among HOMA-IR and metabolic features of the insulin resistance syndrome. While we assessed nondiabetic subjects across a wide range of insulin resistance, our findings are consistent with other reports of no difference in apo(e) isoform or allele frequencies comparing subjects with diabetes (presumably with extreme levels of insulin resistance) to those without diabetes (18, (37) (38) (39) (40) .
Our data confirm the previous work by Despres et al. (14) of an interaction by apo(e) isoform type on the positive association between insulin resistance and fasting triglyceride levels. In that study of 37 nondiabetic women, fasting insulin levels or the insulin area under the curve was positively correlated with triglyceride levels in those with apo(e) isoforms 2/2, 2/3, and 3/3 but not those with apo(e) isoforms 3/4 and 4/4. In our larger population of both women and men, we found a strong positive association between HOMA-IR and triglyceride levels among those with all apo(e) phenotypes, but this association was significantly weaker among those with the e2 phenotype (isoforms 2/2, 2/3) compared with either the e3 or e4 phenotype. Although the pattern of interaction that we observed is different than that reported by Despres et al., our findings support their proposition that the differential affinity of apo(e) and apo(b) receptors for binding apolipoprotein e2-and e4-containing triglyceride-rich lipoproteins influences the expression of hypertriglyceridemia in the hyperinsulinemic state. However, lack of interaction by the apo(e) phenotype on any other insulin resistance syndrome characteristic or lipid risk factors indicates that these effects are strictly limited to triglyceride metabolism.
Studies assessing interactions by apo(e) phenotype on the association between insulin levels or insulin resistance and CHD itself have had contradictory results. In a nested case control analysis of the Multiple Risk Factor Intervention Trial (MRFIT) follow-up cohort, fasting insulin levels were associated with subsequent myocardial infarction or CHD death in men with the apo(e) 3/2 isoform but not in those with the 3/3 or 3/4 isoforms (16). In a cross-sectional analysis of Finnish men with type 2 diabetes, the prevalence of CHD was higher comparing those with the 4/4 and 4/3 isoforms to those with the 3/3, 2/3, or 2/2 isoforms (18) . Another study of Finnish type 2 diabetic patients showed a significantly higher prevalence of CHD comparing those with isoforms 4/4, 4/3, and 3/3 to those with isoforms 2/3 or 2/2 (41). However, other studies of type 2 diabetic patients have found no association between apo(e) phenotype and incident CHD (42) or carotid artery intimal-medial thickness (17) .
Our study has some limitations. We may have misclassified subjects by using apo(e) phenotype, rather than apo(e) genotype. However, we have previously shown that apo(e) phenotyping and genotyping give concordant results in 97% of a random subset of 1,041 of these Framingham Offspring subjects, and that both methods produce similar apo(e) allele frequencies (43) . However, mean triglyceride levels are slightly lower in subjects classified by genotype with apo(e) alleles e2 and e3 and slightly higher in those with apo(e) allele e4 compared with those classified with these alleles by phenotype. These differences would tend to strengthen effects on triglyceride levels observed in this study had the analysis been performed using genotype classification. Offspring insulin resistance status may also have been misclassified by use of the HOMA method, rather than by a more direct method (e.g., insulin clamp or FSIGTT with minimal model analysis). However, data from the Insulin Resistance Atherosclerosis Study suggests that HOMA-IR is a reasonably reliable population level single-sample index of insulin resistance when compared with the FSIGTT method (26) . A single fasting insulin value also has high correlations with FSIGTT-assessed insulin resistance, at least among nondiabetic subjects (44) . Our results were essentially identical when the analysis was repeated using fasting insulin rather than the HOMA-IR distribution. Finally, our results may apply only to Caucasian populations similar to the Framingham Offspring, because apo(e) allele frequencies vary considerably across different ethnic groups (35) . Associations with insulin resistance in other ethnic groups have not been explored.
In conclusion, we found no association between insulin resistance and apo(e) isoform or allele frequencies in a large unselected population of men and women. Further, apo(e) isoform type did not modify associations between insulin resistance and most lipid and nonlipid characteristics of the insulin resistance syndrome. Apo(e) isoform type did modify the association between insulin resistance and fasting triglyceride levels. Insulinemia or insulin resistance and apo(e) phenotype (especially apo(e) allele e4) may be risk factors for CHD, but our data suggest that these risk factors probably exert atherogenic effects through largely unrelated mechanisms.
